Opposite effects of short-term and long-term St John's wort intake on voriconazole pharmacokinetics

Clinical Pharmacology and Therapeutics

Volumn 78, Issue 1, 2005, Pages 25-33

  Rengelshausen, Jens ^b   Banfield, Maria ^b   Riedel, Klaus Dieter ^b   Burhenne, Jürgen ^b   Weiss, Johanna ^b   Thomsen, Torben ^b   Walter Sack, Ingeborg ^b   Haefeli, Walter E ^b   Mikus, Gerd ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; HYPERICUM PERFORATUM EXTRACT; VORICONAZOLE;

ACUTE DRUG ADMINISTRATION; ADULT; ALLELE; AREA UNDER THE CURVE; ARTICLE; CHRONIC DRUG ADMINISTRATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DETERMINATION; DRUG EFFECT; DRUG EXPOSURE; DRUG METABOLISM; DRUG URINE LEVEL; GENOTYPE; HEMOCONCENTRATION; HIGH RISK POPULATION; HUMAN; HYPERICUM PERFORATUM; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; NORMAL HUMAN; PRIORITY JOURNAL; STATISTICAL ANALYSIS; TIME; TREATMENT FAILURE; WILD TYPE;

ADMINISTRATION, ORAL; ADULT; ALLELES; AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; CHROMATOGRAPHY, LIQUID; DRUG ADMINISTRATION SCHEDULE; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; GENOTYPE; HALF-LIFE; HUMANS; HYPERICUM; MALE; METABOLIC CLEARANCE RATE; MIXED FUNCTION OXYGENASES; PATIENT SELECTION; PLANT EXTRACTS; PYRIMIDINES; TIME FACTORS; TRIAZOLES;

EID: 21844435507     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clpt.2005.01.024     Document Type: Article

References (40)

1. P.A.G.M. De Smet Herbal remedies N Engl J Med 347 2002 2046 2056
2. F. Ruschitzka, P. Meier, M. Turina, T. Lüscher, G. Noll Acute heart transplant rejection due to Saint John's wort Lancet 355 2000 548 549
3. U. Schwarz, B. Büschel, W. Kirch Unwanted pregnancy on self medication with St John's wort despite hormonal contraception Br J Clin Pharmacol 55 2003 112 113
4. A. Johne, J. Brockmoller, S. Bauer, A. Maurer, M. Langheinrich, I. Roots Pharmacokinetic and drug disposition pharmacokinetic interaction of digoxin with a herbal extract from St John's wort (Hypericum perforatum) Clin Pharmacol Ther 66 1999 338 345
5. S.C. Piscitelli, A.H. Burstein, D. Chaitt, R.M. Alfaro, J. Falloon Indinavir concentrations and St John's wort Lancet 355 2000 547 548
6. S. Bauer, E. Störmer, A. Johne, H. Krüger, K. Budde, H.-H. Neumayer Alterations in cyclosporin A pharmacokinetics and metabolism during treatment with St John's wort in renal transplant patients Br J Clin Pharmacol 55 2003 203 211
7. G.K. Dresser, U.I. Schwarz, G.R. Wilkinson, R.B. Kim Coordinate induction of both cytochrome P4503A and MDR1 by St John's wort in healthy subjects Clin Pharmacol Ther 73 2003 41 50
8. I. Mai, E. Störmer, S. Bauer, H. Krüger, K. Budde, I. Roots Impact of St John's wort treatment on the pharmacokinetics of tacrolimus and mycophenolic acid in renal transplant patients Nephrol Dial Transplant 18 2003 819 822
9. M.F. Hebert, J.M. Park, Y.-L. Chen, S. Akhtar, A.M. Larson Effects of St. John's wort (Hypericum perforatum) on tacrolimus pharmacokinetics in healthy volunteers J Clin Pharmacol 44 2004 89 94
10. X. Jiang, K.M. Williams, W.S. Liauw, A.J. Ammit, B.D. Roufogalis, C.C. Duke Effect of St John's wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects Br J Clin Pharmacol 57 2004 592 599
11. L.-S. Wang, G. Zhou, B. Zhu, J. Wu, J.-G. Wang, A.M.A. El-Aty St John's wort induces both cytochrome P450 3A4-catalyzed sufoxidation and 2C19-dependent hydroxylation of omeprazole Clin Pharmacol Ther 75 2004 191 197
12. C. Tannergren, H. Engman, L. Knutson, M. Hedeland, U. Bondesson, H. Lennernäs St John's wort decreases the bioavailability of R- and S-verapamil though induction of the first-pass metabolism Clin Pharmacol Ther 75 2004 298 309
13. R.F. Frye, S.M. Fitzgerald, T.F. Lagattuta, M.W. Hruska, M.J. Egorin Effect of St John's wort on imatinib mesylate pharmacokinetics Clin Pharmacol Ther 76 2004 323 329
14. D. Dürr, B. Stieger, G.A. Kullak-Ublick, K.M. Rentsch, H.C. Steinert, P.J. Meier St John's wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4 Clin Pharmacol Ther 68 2000 598 604
15. L. Henderson, Q.Y. Yue, C. Bergquist, B. Gerden, P. Arlett St John's wort (Hypericum perforatum) drug interactions and clinical outcomes Br J Clin Pharmacol 54 2002 349 356
16. M. Wurglics, K. Westerhoff, A. Kaunzinger, A. Wilke, A. Baumeister, J. Dressman Comparison of German St. John's wort products according to hyperforin and total hypericin content J Am Pharm Assoc 41 2001 560 566
17. S.C. Mueller, B. Uehleke, H. Woehling, M. Petzsch, J. Majcher-Peszynska, E.-M. Hehl Effect of St John's wort dose and preparations on the pharmacokinetics of digoxin Clin Pharmacol Ther 75 2004 546 557
18. I. Mai, S. Bauer, E.S. Perloff, A. Johne, B. Uehleke, B. Frank Hyperforin content determines the magnitude of the St John's wort-cyclosporine drug interaction Clin Pharmacol Ther 76 2004 330 340
19. B.J. Komoroski, S. Zhang, H. Cai, M. Hutzler, R. Frye, T.S. Tracy Induction and inhibition of cytochromes P450 by the St. John's wort constituent hyperforin in human hepatocyte cultures Drug Metab Dispos 32 2004 512 518
20. L.B. Moore, B. Goodwin, S.A. Jones, G.B. Wisely, C.J. Serabjit-Singh, T.M. Willson St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor Proc Natl Acad Sci U S A 97 2000 7500 7502
21. R.S. Obach Inhibition of human cytochrome P450 enzymes by constituents of St. John's wort, an herbal preparation used on the treatment of depression J Pharmacol Exp Ther 294 2000 88 95
22. L. Zou, M.R. Harkey, G.L. Henderson Effects of herbal components on cDNA-expressed cytochrome P450 enzyme catalytic activity Life Sci 71 2002 1579 1589
23. L.B. Johnson, C.A. Kauffmann Voriconazole a new triazole antifungal agent Clin Infect Dis 36 2003 630 637
24. R. Herbrecht, D.W. Denning, T.F. Patterson, J.E. Bennett, R.E. Greene, J.-W. Oestmann Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis N Engl J Med 347 2002 408 415
25. R. Hyland, B.C. Jones, D.A. Smith Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole Drug Metab Dispos 31 2003 540 547
26. Y. Ikeda, K. Umemura, K. Kondo, K. Sekiguchi, S. Miyoshi, M. Nakashima Pharmacokinetics of voriconazole and cytochrome P450 2C19 genetic status Clin Pharmacol Ther 75 2004 586 588
27. Z. Desta, X. Zhao, J.-G. Shin, D.A. Flockhart Clinical significance of the cytochrome P450 2C19 genetic polymorphism Clin Pharmacokinet 41 2002 913 958
28. L.-S. Wang, B. Zhu, A.M.A. El-Aty, G. Zhou, Z. Li, J. Wu The influence of St. John's wort on CYP2C19 activity with respect to genotype J Clin Pharmacol 44 2004 577 581
29. G.J. Pennick, M. Clark, D.A. Sutton, M.G. Rinaldi Development and validation of a high-performance liquid chromatography assay for voriconazole Antimicrob Agents Chemother 47 2003 2348 2350
30. M. Martin-Facklam, K. Rieger, K.-D. Riedel, J. Burhenne, I. Walter-Sack, W.E. Haefeli Undeclared exposure to St. John's wort in hospitalized patients Br J Clin Pharmacol 58 2004 437 441
31. Z. Wang, C. Gorski, M.A. Hamman, S.-W. Huang, L.J. Lesko, S.D. Hall The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity Clin Pharmacol Ther 70 2001 317 326
32. T. Miyama, H. Takanaga, H. Matsuo, K. Yamano, K. Yamamoto, T. Iga P-glycoprotein-mediated transport of itraconazole across the blood-brain barrier Antimicrob Agents Chemother 42 1998 1738 1744
33. C.K. Finch, C.R. Chrisman, A.M. Baciewicz, T.H. Self Rifampin and rifabutin drug interactions an update Arch Intern Med 162 2002 985 992
34. Z. Wang, M.A. Hamman, S.M. Huang, L.J. Lesko, S.D. Hall Effect of St John's wort on the pharmacokinetics of fexofenadine Clin Pharmacol Ther 71 2002 414 420
35. E. Wang, M. Barecki-Roach, W.W. Johnson Quantitative characterization of direct P-glycoprotein inhibition by St John's wort constituents hypericin and hyperforin J Pharm Pharmacol 56 2004 123 128
36. Y. Tayrouz, R. Ding, J. Burhenne, K.D. Riedel, J. Weiss, T. Hoppe-Tichy Pharmacokinetic and pharmaceutic interaction between digoxin and Cremophor RH40 Clin Pharmacol Ther 73 2003 397 405
37. L. Purkins, N. Wood, P. Ghahramani, K. Greenhalgh, M.J. Allen, D. Kleinermans Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regime Antimicrob Agents Chemother 46 2002 2546 2553
38. S.J. Roffey, S. Cole, P. Comby, D. Gibson, S.G. Jezequel, A.N.R. Nedderman The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog, and human Drug Metab Dispos 31 2003 731 741
39. Y. Chen, S.S. Ferguson, M. Negishi, J.A. Goldstein Identification of constitutive androstane receptor and glucocorticoid receptor binding sites in the CYP2C19 promoter Mol Pharmacol 64 2003 316 324
40. I. Lutsar, M.R. Hodges, K. Tomaszewski, P.F. Troke, N.D. Wood Safety of voriconazole and dose individualization Clin Infect Dis 36 2003 1087 1088